First drug to treat underlying cause of cystic fibrosis approved in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Vertex Pharmaceuticals' Kalydeco (ivacaftor; previously known as VX-770) as the first medicine to treat the underlying cause of cystic fibrosis (CF).